Use of Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for Mutant Non-Small Cell Lung Cancer.

Purpose: Evaluating drug responses using primary patient-derived cells represents a potentially rapid and efficient approach to screening for new treatment approaches. Here, we sought to identify neratinib combinations in mutant non-small cell lung cancer (NSCLC) patient enograft-erived rganotypic pheroids (XDOTS) using a short-term system.

Experimental Design: We generated two mutant NSCLC PDX models [DFCI359 ( exon19 755_757LREdelinsRP) and DFCI315 ( exon20 V777_G778insGSP)] and used the PDX tumors to generate XDOTS.